Gamida Cell plans to use the proceeds to complete NiCord’s Phase 3 clinical trial and prepare for product commercialization by expanding its in-house manufacturing capacity, and the company’s presence in the US, as well as continuing to develop additional pipeline products such as CordIn for rare genetic diseases and NK cells as a treatment for cancer.
“The financing announced today provides important support for Gamida Cell’s innovative product pipeline, which has the potential to change the clinical application of cell based therapies. We are excited to take Gamida Cell to the next step towards becoming a commercial global company based on innovative oncology therapy,” said Gamida Cell’s chairman of the board Julian Adams, Ph.D.
Gary Leibler, founder and managing partner of Shavit Capital, said, “Gamida Cell has a highly impressive management team, shareholder base and board of directors. These, combined with the strong clinical data of the Company’s pipeline products, attracted the attention of first tier international financial investors and pharmaceutical companies. Gamida Cell is now on course to complete its primary goal of developing its flagship product, NiCord, to address a multi-billion dollar market and help the many patients in need of better therapies.”
Andrew Ng, Head of Healthcare of VMS Investment Group, added, “We are pleased to join this distinguished group of investors and support this promising company. As a Hong Kong-based investment group with a strong healthcare presence and network in Asia, we are committed to supporting Gamida Cell with its Asia development and ultimately enabling more patients with high-risk blood cancers to benefit from this life-saving technology.”
Published by Globes [online], Israel business news – www.globes-online.com – on June 19, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017